CCM
AVTX icon

CAAS Capital Management’s Avalo Therapeutics AVTX Stock Holding History

CAAS Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4
Closed -$26K – 866
2021
Q3 		$26K Buy
+4
New +$32.4K ﹤0.01% 855

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

CAAS Capital Management's AVTX Position: Q4 2021 in Review

CAAS Capital Management sold out of Avalo Therapeutics (AVTX) in Q4 2021, closing a stake of 4 shares — an estimated $26K sold.

CAAS Capital Management first reported a position in AVTX in Q3 2021 and held it in 1 quarter. The position peaked at $26K in Q3 2021. 70 funds tracked by Wall St. Rank hold AVTX as of Q4 2021.

  • CAAS Capital Management reported no remaining Avalo Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 4 Avalo Therapeutics shares in Q4 2021, an estimated $26K.
  • CAAS Capital Management first reported a position in Avalo Therapeutics in Q3 2021 and held it in 1 quarter.
  • CAAS Capital Management's Avalo Therapeutics position peaked at $26K in Q3 2021.
  • 70 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.